CymaBay Therapeutics ROA 2013-2018 | CBAY

Current and historical return on assets (ROA) values for CymaBay Therapeutics (CBAY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. CymaBay Therapeutics ROA for the three months ending December 31, 2018 was -34.51%.
CymaBay Therapeutics ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-12-31 $-0.07B $0.19B -34.72%
2018-09-30 $-0.06B $0.20B -31.13%
2018-06-30 $-0.05B $0.22B -29.18%
2018-03-31 $-0.04B $0.23B -33.99%
2017-12-31 $-0.03B $0.10B -42.86%
2017-09-30 $-0.03B $0.10B -69.46%
2017-06-30 $-0.03B $0.02B -122.73%
2017-03-31 $-0.03B $0.03B -101.01%
2016-12-31 $-0.03B $0.02B -97.30%
2016-09-30 $-0.03B $0.03B -77.04%
2016-06-30 $-0.03B $0.03B -65.41%
2016-03-31 $-0.02B $0.04B -50.63%
2015-12-31 $-0.02B $0.04B -38.46%
2015-09-30 $-0.02B $0.05B -58.67%
2015-06-30 $-0.02B $0.03B -60.27%
2015-03-31 $-0.02B $0.04B -67.13%
2014-12-31 $-0.03B $0.04B -92.09%
2014-09-30 $0.19B $0.05B 571.85%
2014-06-30 $0.24B $0.03B 793.44%
2014-03-31 $0.24B $0.03B 1000.00%
2013-12-31 $0.24B $0.03B 1501.54%
2013-09-30 $0.03B $0.03B 400.00%
2013-06-30 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.791B $0.010B
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $51.256B 9.23
Teva Pharmaceutical Industries (TEVA) Israel $17.195B 5.93
Mylan (MYL) United Kingdom $14.766B 6.25
Bausch Health Cos (BHC) Canada $9.196B 6.54
Dr Reddy's Laboratories (RDY) India $6.567B 26.19
Supernus Pharmaceuticals (SUPN) United States $1.989B 18.46
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.936B 3.15
Homology Medicines (FIXX) United States $1.018B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.964B 89.61
Voyager Therapeutics (VYGR) United States $0.600B 0.00
Assembly Biosciences (ASMB) United States $0.508B 0.00
Akorn (AKRX) United States $0.451B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.392B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.219B 0.00
Sol-Gel Technologies (SLGL) Israel $0.129B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.117B 0.00
Acasti Pharma (ACST) Canada $0.084B 0.00
Teligent (TLGT) United States $0.069B 0.00
Agile Therapeutics (AGRX) United States $0.069B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.064B 0.00
Evoke Pharma (EVOK) United States $0.026B 0.00
Aevi Genomic Medicine (GNMX) United States $0.015B 0.00
China Pharma Holdings (CPHI) China $0.014B 0.00